Tanios S. Bekaii-Saab
Mayo Clinic
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Tanios S. Bekaii-Saab as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:40 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07226856 · BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic AdenocarcinomaMayo Clinic · recruiting · Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 · principal investigator
- Ph1/Ph2NCT03337087 · Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary CancerAcademic and Community Cancer Research United · unknown · Metastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:40 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Gastrointestinal Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2019 to 2024 · $41,637 awarded in 2024Grant number is on one of their registry trials
Most cited trial papers
Clinical-trial papers with this author name in pancreatic cancer, ranked by citations from NIH iCite, fetched 2026-11-12 13:40 UTC. The ranking covers the 200 most relevant of 8 PubMed records, and a shared surname and initials can bring in a namesake. All 8 on PubMed
- Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma.Mol Ther · 2016135 citationsRCR 3.9
- 60 citationsRCR 1.6
- Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma.J Immunother Cancer · 202338 citationsRCR 2.5
- Quality of life in a prospective, multicenter phase 2 trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinoma.Int J Radiat Oncol Biol Phys · 201431 citationsRCR 0.9
- 30 citationsRCR 0.7
- 20 citationsRCR 0.5
- Nanoliposomal irinotecan (Nal-IRI)-based chemotherapy after irinotecan -based chemotherapy in patients with pancreas cancer.Pancreatology · 20217 citationsRCR 0.3